Skip to content
Search

Latest Stories

Submit Guest Post

India syringe maker boosts production to meet virus vaccine demand

INDIA's biggest syringe manufacturer is ramping up production to churn out a billion units, anticipating a surge in demand as the global race to find a coronavirus vaccine heats up.

While the focus on tackling the pandemic has mostly been on the development of vaccines, experts say medical essentials to administer them are also vital.


Hindustan Syringes -- one of the world's largest makers of the item -- said it is increasing its output of auto-disable devices (which prevent re-use) from 700 million a year to one billion by 2021 to meet the expected demand.

"Even if 60 per cent of the world's population is immunised, it would mean four to five billion syringes would be required," Hindustan Syringes managing director Rajiv Nath told AFP at their factory in northern Haryana state.

There are currently more than 30 candidate vaccines being tested on humans, with governments hoping to deploy one as soon as possible with the coronavirus wrecking lives and economies.

Shortages of PPE such as masks hampered early responses to the pandemic, and countries have now started building up their stockpile of syringes, vials and needles.

"We may have sufficient capacity for the first wave of vaccines which would only be administered to priority groups," Prashant Yadav, a healthcare supply chains expert at Harvard Medical School, said.

"(But) when we get to a large-scale vaccination in late 2021 or 2022 and the dose demand estimates would be greater than 10 billion, that's when syringe supply starts becoming a constraint."

So far, UNICEF has ordered 140 million syringes from Hindustan for COVAX, a global initiative aimed at ensuring a more equitable distribution of vaccines to poorer nations.

Much of the world's demand for syringes is expected to be met by factories in China and India.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

JLR BYD battle

Jaguar Land Rover is challenging BYD over the design of its Ti7 plug-in hybrid SUV, which has drawn comparisons with the iconic Land Rover Defender

Getty Images

JLR raids BYD offices in escalating battle over China's alleged Defender lookalike

  • Court-appointed bailiffs seized digital records from BYD offices in the Netherlands in August as part of JLR's intellectual property dispute.
  • BYD's seven-seat Ti7 is expected to launch in the UK in January at £47,995, compared with £68,465 for a Defender 110.
  • Chinese carmakers are gaining ground in Britain, with the Jaecoo 7 becoming the country's best-selling car in October.

Jaguar Land Rover (JLR) has stepped up its legal battle with Chinese automotive giant BYD after court-appointed bailiffs seized digital records from the rival's offices in the Netherlands over allegations that its new SUV copies the design and technology of the Land Rover Defender.

The dispute centres on BYD's seven-seat Ti7 plug-in hybrid, which has attracted comparisons with the iconic British off-roader because of its boxy profile and rugged styling.

Keep ReadingShow less